OM blog - Did GlaxoSmithKline silence physician?

Submitted by Dean Giustini on June 8, 2007 - 01:38

Dr. John B. Buse, incoming President of the American Diabetes Association, has had a run-in with big Pharma and GlaxoSmithKline. A vocal critic of the diabetes drug Avandia - rosiglitazone, Buse says the drug raises patients' risk of heart attacks; he also sharply criticizes marketing of the drug, and Glaxo's "blatant selective manipulation of data".

OM blog - Google vs. PubMed?

Submitted by Dean Giustini on June 6, 2007 - 05:05

[img_assist|nid=25|title=Search the Web|desc=|link=node|align=left|width=100|height=99]

As a medical librarian, I am often asked to comment about what to use, Google or PubMed? My recommendation is always to learn how to use both - but keep in mind that they are vastly different tools, with different benefits and limitations. Doctors should know what some of those are given their information needs.

OM blog - PubMedCentral Canada?

Submitted by Dean Giustini on June 4, 2007 - 17:36

The United States' National Institutes of Health maintains a fulltext archive and repository for medical journals and articles, entitled PubMedCentral. In the United Kingdom, there is the Wellcome Trust's U.K. PubMedCentral project - can a Canadian project/version of PMC be far behind?

OM blog - A better way to find

Submitted by Dean Giustini on June 2, 2007 - 03:23

[img_assist|nid=22|title=A better way|desc=|link=node|align=left|width=100|height=100]

Canadian researchers are among the world's best-known advocates of access to information in the Internet age. (See Steven Harnard's website on OA.) As a medical librarian, I have witnessed a number of paradigm shifts in access over the course of my career, especially those related to digital access on the Internet starting in the mid-1990s.

Using social software - do physicians?

Submitted by Dean Giustini on May 29, 2007 - 01:03

We had a successful session at today's continuing education (CE) course, held at the University of Ottawa Library. (A great computer lab complete with projected sound.) It was an interesting learning experience for me as a teacher, particularly as I try to see how the dynamics of the classroom can be facilitated, or not, and the implications of the learning theories I am studying when applied to my practice.

Podcasting and Web 2.0 for physicians, librarians

Submitted by Dean Giustini on May 25, 2007 - 00:39

Authored by my health librarian colleague in Winnipeg, Judy Inglis, and I, the Canadian Health Libraries Association (CHLA/ABSC) has published the following New Factsheet on Podcasting for health librarians and physicians. Feel free to copy from it freely. (See also: American health librarian, Michelle Kraft's List of Podcasts and Vodcasts).

All Open Access Is Not Equal

Submitted by Dean Giustini on May 20, 2007 - 15:29

[img_assist|nid=18|title=The Access Principle|desc=|link=node|align=left|width=73|height=100]One of the major principles of open access (OA) is that authors (and researchers) are much more likely to read (and therefore cite) articles made available under OA models. Is this true? What is the evidence proving this assertion? With the proliferation of OA models in science and medical publishing (and different business models), some readers have expressed confusion about OA and how it is defined.

Thus, let's start with two basic kinds of OA:

OM blog - Start with the patient

Submitted by Dean Giustini on May 15, 2007 - 13:02

Evidence-based medicine, it's often said, begins and ends with care of the patient.

OM blog - Scientific American and Guyatt article

Submitted by Dean Giustini on May 11, 2007 - 03:55

"Scientific American" has published an article about the Guyatt systematic review from our first issue.  It quotes Patty Groome, an epidemiologist at Queens University Cancer Research Institute in Kingston, Ontario, and

OM blog - Advertising, and big Pharma

Submitted by Dean Giustini on May 4, 2007 - 23:38

[img_assist|nid=14|title=Drug development|desc=|link=node|align=left|width=100|height=75]Few topics in medicine are as contentious as the marketing and selling of pharmaceuticals. On one side, advocates of the drug industry (whose combined profits were over $600 billion in 2006) suggest that drug companies do enormous social good through philanthropic efforts, foreign aid and through their donation of drugs to developing countries - fluconazole, for example, to AIDS patients in Africa.